Neurophysiological analysis of ADHD: an exploratory neuroimaging study using functional near-infrared spectroscopy (fNIRS)

Neurophysiological analysis of ADHD: an exploratory neuroimaging study using functional near-infrared spectroscopy (fNIRS) - Clinically-oriented monitoring of acute effects of Atomoxetine (ATX) on cerebral hemodynamics in ADHD children: an exploratory fNIRS study using a target detection task

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014036

Enrollment

Registered

2014-06-01

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder

Interventions

washout (more than 2 days) - ATX (1 day) washout (more than 2 days) - placebo (1 day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All subjects meet the following criteria. (1) Subjects are under 16 years old and more than 6 years old. Regardless of sex and treatment before this trial. (2) Subjects are diagnosed with ADHD based on DSM-IV or V through an interview with more than two pediatric neurologists. (3) Written informed consent was obtained from the parents of all subjects, and the study was approved by the Ethics Committee of Jichi Medical University Hospital, Japan. (4) The Wechsler Intelligence Scale of Children-Third Edition (WISC-III or IV) full IQ scores of subjects are over 70

Exclusion criteria

Exclusion criteria: (1) Subjects who are diagnosed with anxiety disorder (2) Subjects who are diagnosed with glaucoma (3) Subjects who are diagnosed with hyperthyroidism (4) Subjects who have angina, arrhythmia (5) Subjects who have allergies to ATX (6) Subjects who are diagnosed with tics or Tourette's syndrome, or have family history of Tourette's syndrome (7) Subjects who are diagnosed with severe depression (8) Subjects who are diagnosed with pheochromocytoma (9) Subjects who current or past use of monoamine oxidase inhibitor (MAOI)

Design outcomes

Primary

Measure	Time frame
(1) fNIRS analysis Comparison of frontal activation (oxy-Hb, deoxy-Hb and total-Hb, measured by fNIRS) before and after an acute clinical dose of ATX or placebo (90 min after ATX administration) (2) Behavioral performance Comparison of reaction time and percentage of correct response on target detection task before and after the acute clinical dose of ATX or placebo (90 min after ATX administration)	—

Measure

Time frame

(1) fNIRS analysis Comparison of frontal activation (oxy-Hb, deoxy-Hb and total-Hb, measured by fNIRS) before and after an acute clinical dose of ATX or placebo (90 min after ATX administration) (2) Behavioral performance Comparison of reaction time and percentage of correct response on target detection task before and after the acute clinical dose of ATX or placebo (90 min after ATX administration)

—

Secondary

Measure	Time frame
The response of continuous administration of ATX on ADHD rating scale and Questionnaire-Children with Difficulties	—

Countries

Japan

Contacts

Public ContactEiju Watanabe

Jichi Medical University Neurosurgery

eiju@jichi.ac.jp0285-58-7373

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026